🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Pacific Biosciences of California, Inc. PACB R2K

Healthcare · Medical Devices · United States
https://www.pacb.com

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

READ MORE ›
$1.49
+55.21% 1Y

Market & Price

Market Cap
$462.80M
Current Price
$1.49
High / Low (52W)
$2.67 / $0.96
Beta
2.40

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.01
Price to Book
186.25
P/S
2.89
EV/EBITDA
-6.24
Dividend Yield
-

Profitability & Returns

ROCE
-75.80%
ROE
-
ROA
-11.96%
Profit Margin
-80.34%
Op Margin
-
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-0.41

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
4.67
Current Ratio
5.65
Debt
$706.39M
Total Assets
$784.08M
Current Assets
$375.05M
Working Capital
$302.22M

Ownership

Promoter Holding
8.77%
Chg in Prom Hold
-
FII / Inst Holding
54.04%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$893.22M
Total Revenue (TTM)
$160.03M
EBITDA
$-143.15M
Free Cash Flow
$-48.24M
Operating Cash Flow
$-111.84M
Shares Outstanding
310.60M
Gross Margin
38.33%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
7.64%
Profit 5Y
-24.62%
Revenue (YoY)
0.10%
Earnings (YoY)
-

PROS

No notable strengths flagged.

CONS

  • Earnings shrank at -24.6% CAGR over 5 years.
  • Trading 44.2% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PACB Pacific Biosciences of California, Inc. R2K 1.49 - $462.80M - -75.80% - 7.64% -24.62%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------24.91M20.07M23.55M-19.36M21.58M18.16M-16.43M24.62M21.91M-15.60M19.08M19.08M29.00M30.61M34.89M33.17M35.47M32.31M38.90M47.57M55.69M38.81M36.01M-37.15M39.77M38.44M44.65M37.18M
Cost of Revenue -----------------------------------38.52M25.08M22.54M28.08M24.34M
Gross Profit 5.93M14.51M6.55M26.47M9.50M10.64M12.64M11.37M8.94M8.00M8.23M9.49M7.30M8.86M3.19M5.75M5.12M9.61M6.91M12.93M7.49M6.61M7.06M12.98M13.75M15.36M14.15M16.19M13.55M9.76M15.55M17.90M11.28M5.94M--1.37M14.68M15.90M16.57M12.84M
Operating Expenses -----------------------------------431.26M59.54M54.78M57.76M66.99M
Operating Income -19.33M-11.36M2.61M-1.06M-18.57M-18.07M-16.73M-17.87M-23.30M-24.39M-21.57M-20.53M-23.95M-21.75M-24.67M-30.62M-30.13M-24.38M-28.11M-17.92M-32.71M-23.52M-24.18M-33.71M-37.57M-74.48M-77.52M-67.97M-74.62M-91.25M-73.17M-82.49M-81.36M-175.85M--432.63M-44.85M-38.88M-41.20M-54.15M
EBITDA ------------------------------------51.86M-35.58M-31.48M-33.78M-2.28M
Interest Expense -----------------------------------1.74M1.74M1.74M1.74M1.74M
Pretax Income ------------------------------------426.38M-41.90M-37.62M-40.17M-8.09M
Tax Provision ------------------------------------302.00K35.00K383.00K202.00K184.00K
Net Income -20.17M-11.94M1.82M-1.41M-19.35M-18.50M-17.49M-19.03M-23.87M-25.54M-22.02M-20.76M-24.18M-22.54M-25.04M-30.80M-30.32M-24.60M-29.12M-91.00K1.26M-23.09M-23.71M-87.44M-41.00M16.54M-81.50M-71.39M-76.97M-88.02M-69.83M-66.87M-78.18M-173.32M--426.07M-41.93M-38.00M-40.37M-8.28M
Diluted EPS --0.02----0.19----------0.20---0.01-0.15-0.14-0.45-0.210.08-0.37-0.32-0.34-0.36-0.28-0.26-0.29-0.64--1.44-0.14-0.13-0.13-0.03
R&D Expense 14.48M15.04M16.16M-16.36M17.52M17.48M-16.97M16.88M15.84M-16.31M15.66M14.36M-15.48M14.91M14.96M-15.25M15.01M16.47M20.55M22.27M27.51M52.94M50.35M47.09M48.94M46.17M47.51M43.45M38.48M25.52M29.05M22.53M22.85M-19.61M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------90.71M93.47M78.63M---128.30M200.52M154.01M160.00M
Cost of Revenue -------------79.27M147.74M116.73M114.22M
Gross Profit 135.00K1.67M13.03M940.00K6.42M23.40M53.45M44.16M34.66M25.10M34.58M32.57M-49.03M52.78M37.28M45.78M
Operating Expenses -------------353.85M363.14M327.94M603.34M
Operating Income ---109.76M-94.34M-77.54M-62.85M-29.13M-71.24M-89.78M-100.99M-100.55M-104.39M--304.82M-310.37M-290.66M-557.56M
EBITDA --------------282.24M-277.28M-242.77M-152.69M
Interest Expense -------------14.69M14.34M13.41M6.95M
Pretax Income --------------314.25M-318.16M-309.54M-546.06M
Tax Provision -------------0-11.42M316.00K318.00K
Net Income -87.70M-140.17M-109.39M-94.47M-79.29M-66.16M-31.70M-74.38M-92.19M-102.56M-84.13M29.40M--314.25M-306.74M-309.85M-546.38M
Diluted EPS ----------0.76-0.550.17--1.40-1.21-1.58-1.82
R&D Expense 75.88M111.82M76.08M47.62M45.22M48.23M60.44M67.62M65.32M62.59M59.63M64.15M112.90M193.00M187.17M134.92M97.31M

Compounded Sales Growth

5 Years:7.64%
1 Year:0.10%

Compounded Profit Growth

5 Years:-24.62%
1 Year:-

Stock Price Performance

1 Year:+55.21%
6 Months:-43.35%
3 Months:-11.31%
1 Month:+1.36%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --305.75M218.32M129.68M136.19M124.39M131.11M137.88M144.08M170.28M147.99M413.98M-1.77B1.75B1.26B784.08M
Current Assets --------------852.07M742.05M495.68M375.05M
Cash & Equivalents 78.46M89.23M147.65M58.87M46.54M26.36M36.45M33.63M16.77M16.51M18.84M29.63M81.61M-325.09M179.91M55.37M63.71M
Inventory --------------50.38M56.68M58.76M49.28M
Receivables --------------18.79M36.62M27.52M35.45M
Total Liabilities --25.88M26.85M20.30M67.00M69.44M57.57M53.22M57.98M56.21M93.07M78.49M-1.20B1.04B753.85M778.73M
Current Liabilities --20.84M19.38M14.74M22.55M31.49M38.18M33.77M28.64M26.88M49.15M38.50M-263.33M95.03M66.30M72.83M
Long Term Debt --2.93M2.79M2.61M13.35M--------896.68M892.24M647.49M645.38M
Total Debt --------------948.48M933.93M672.43M702.42M
Total Equity -93.39M-177.12M279.87M191.46M109.38M69.18M54.95M73.54M84.67M86.10M114.06M54.92M335.49M-562.90M701.30M506.59M5.35M
Shares Outstanding --------------226.50M267.74M294.42M301.96M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -74.84M-122.00M-102.97M-76.82M-29.83M---67.93M-67.52M-66.43M-78.31M19.50M--263.21M-259.17M-206.06M-111.21M
Investing Cash Flow 18.59M-138.25M6.45M61.79M-33.12M---14.86M-1.55M-38.41M62.05M-219.32M-116.08M4.60M124.00M115.45M
Financing Cash Flow 67.01M318.66M7.74M2.71M42.77M--65.93M68.81M107.18M26.55M251.84M-9.62M108.89M-42.99M3.43M
Capital Expenditure -5.18M-5.26M-9.28M-1.70M-909.00K-1.61M-3.01M-8.21M-10.43M-1.85M-2.84M-1.04M--16.93M-8.84M-6.19M-7.71M
Free Cash Flow -80.02M-127.25M-112.26M-78.53M-30.74M---76.14M-77.95M-68.28M-81.15M18.46M--280.14M-268.02M-212.25M-118.92M
Net Change in Cash --------------137.51M-145.68M-125.04M7.67M
Share Buybacks 8.00K----------------

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------48.7%37.1%31.9%---38.2%26.3%24.2%28.6%
Operating Margin % --------78.5%-96.1%-128.4%----237.6%-154.8%-188.7%-348.5%
Net Margin % --------82.0%-98.6%-130.4%----244.9%-153.0%-201.2%-341.5%
ROE % 49.5%-50.1%-57.1%-86.4%-114.6%-120.4%-43.1%-87.8%-107.1%-89.9%-153.2%8.8%--55.8%-43.7%-61.2%-10,214.5%
ROCE % ---55.2%-82.1%-68.2%-67.7%-31.4%-68.4%-77.8%-70.4%-101.7%-27.8%--20.3%-18.8%-24.3%-78.4%

Shareholding Pattern

Insiders
8.77%
Institutions
54.04%
Public Float
59.24%

Top Institutional Holders

#Holder% HeldSharesValue
1 ARK Investment Management, LLC 11.68% 36.27M $54.05M
2 Blackrock Inc. 8.13% 25.27M $37.65M
3 Softbank Group Corporation 6.58% 20.45M $30.47M
4 Vanguard Capital Management LLC 4.11% 12.78M $19.04M
5 Sumitomo Mitsui Trust Group, Inc. 2.27% 7.04M $10.49M
6 Amova Asset Management Americas Inc 2.27% 7.04M $10.49M
7 Geode Capital Management, LLC 2.25% 6.98M $10.39M
8 State Street Corporation 1.97% 6.12M $9.12M
9 Millennium Management Llc 1.58% 4.89M $7.29M
10 Shaw D.E. & Co., Inc. 1.17% 3.64M $5.42M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PACB

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks